Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05039710
Other study ID # CR109081
Secondary ID 75220795NAS1002
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 8, 2021
Est. completion date February 22, 2023

Study information

Verified date May 2023
Source Janssen Pharmaceutical K.K.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of single subcutaneous (SC) dose of JNJ-75220795 in Japanese participants.


Recruitment information / eligibility

Status Terminated
Enrollment 9
Est. completion date February 22, 2023
Est. primary completion date February 17, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 65 Years
Eligibility Inclusion Criteria: - Participants with certain genetic predispositions to non-alcoholic fatty liver disease (NAFLD) determined at screening - Presence of liver steatosis at screening - Participants on anti-hypertensive and/or lipid lowering medications and/or glucose lowering medications must be on stable dose(s) for at least 4 weeks prior to screening - Body mass index between 18 kilograms per meter square (kg/m^2) and 40 kg/m^2 inclusive, and body weight stable defined as no more than 5 percent (%) body weight loss or gain within 3 months prior to screening (based on participant's report) and no more than 5% body weight loss or gain from screening to randomization Exclusion Criteria: - Known allergies, hypersensitivity, or intolerance to excipients - History of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (anti-HCV) positive, or other clinically active liver disease, or tests positive for HbsAg or anti-HCV at screening. And/or history of human immunodeficiency virus (HIV) antibody positive, or tests positive for HIV or syphilis at screening - Participants with clinical or biochemical (international normalized ratio [INR] greater than [>] 1.2, or platelet count less than [<] lower limits of normal [LLN]) evidence of hepatic decompensation at screening or baseline - Estimated glomerular filtration rate (eGFR) by Japanese eGFR formula below 60 milliliters per minute [mL/min] at screening - Thyroid stimulating hormone (TSH) levels, free triiodothyronine (FT3) and free thyroxine (FT4) outside normal limits of the clinical laboratory's reference range at screening

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
JNJ-75220795
JNJ-75220795 will be administered as SC injection.
Other:
Placebo
Matching placebo will be administered as SC injection.

Locations

Country Name City State
Japan Souseikai Fukuoka Mirai Hospital Fukuoka-shi
Japan Corporation Heishinkai ToCROM Clinic Shinjuku-ku
Japan Corporation Heishinkai OCROM Clinic Suita-city
Japan Sumida Hospital Tokyo

Sponsors (1)

Lead Sponsor Collaborator
Janssen Pharmaceutical K.K.

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants with Treatment-emergent Signs and Symptoms/Adverse Events (AEs) Number of participants with treatment-emergent signs and symptoms/adverse events (including allergic reactions/hypersensitivity and local injection site reactions) will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Treatment-emergent adverse events (TEAEs) are defined as AEs with onset or worsening on or after date of first dose of study treatment. Up to Day 168
Primary Number of Participants With Change From Baseline in Vital Signs Abnormalities Number of participants with change from baseline in vital signs abnormalities including body temperature (axillary), pulse, respiratory rate and blood pressure will be reported. Baseline, Up to Day 168
Primary Number of Participants With Change From Baseline in Clinical Laboratory Abnormalities Number of participants with change from baseline in clinical laboratory abnormalities including hematology, serum chemistry and urinalysis will be reported. Baseline, Up to Day 168
Primary Number of Participants With Change From Baseline in Physical Examination Abnormalities Number of participants with change from baseline in physical examination abnormalities will be reported. Baseline, Up to Day 168
Primary Number of Participants With Change From Baseline in Electrocardiogram (ECG) Abnormalities Number of participants with change from baseline in ECG abnormalities will be reported. Baseline, Up to Day 168
Secondary Percent Change in Liver Fat Content Measured by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) Percent change in liver fat content as measured by MRI-PDFF will be reported. From Baseline to Weeks 6, 12, 18, and 24
Secondary Maximum Observed Plasma Concentration (Cmax) of JNJ-75220795 Cmax of JNJ-75220795 will be reported. Predose up to 48 hours postdose (up to Day 3)
Secondary Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-75220795 Tmax of JNJ-75220795 will be reported. Predose up to 48 hours postdose (up to Day 3)
Secondary Apparent Elimination Half-Life (t1/2) of JNJ-75220795 t1/2 is defined as apparent elimination half-life associated with the terminal slope of the semilogarithmic drug concentration-time curve. Predose up to 48 hours postdose (up to Day 3)
Secondary Area Under the Plasma Concentration Time Curve of JNJ-75220795 from Time Zero to Infinite time (AUC [0-Infinity]) AUC (0-Infinity) is defined as the area under the plasma concentration versus time curve of JNJ-75220795 from time zero to infinite time. Predose up to 48 hours postdose (up to Day 3)
Secondary Area Under the Plasma Concentration versus Time Curve of JNJ-75220795 from Time Zero to Time of the Last Measurable Concentration (AUC [0-Last]) AUC (0-Last) is defined as area under the plasma concentration versus time curve of JNJ-75220795 from time zero to time of the last measurable concentration. Predose up to 48 hours postdose (up to Day 3)
Secondary Total Apparent Clearance (CL/F) of JNJ-75220795 CL/F is defined as total apparent clearance of JNJ-75220795. Predose up to 48 hours postdose (up to Day 3)
Secondary Apparent Volume of Distribution (Vd/F) of JNJ-75220795 Vd/F is defined as apparent volume of distribution of JNJ-75220795. Predose up to 48 hours postdose (up to Day 3)
Secondary Number of Participants with Treatment Emergent Anti-drug Antibody (ADA) Number of participants with treatment emergent ADA will be reported. Up to Day 168
See also
  Status Clinical Trial Phase
Recruiting NCT05979779 - Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis Phase 2
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Not yet recruiting NCT05984745 - Effect of CoQ10 on the Outcome of MAFLD Patients Phase 2
Completed NCT02565446 - Transforming Non-Invasive Liver Disease Detection by MRE: The Hepatogram N/A
Not yet recruiting NCT01694342 - Telomere Parameters in Patients With Nonalcoholic Fatty Liver N/A
Completed NCT01464801 - Resveratrol in Patients With Non-alcoholic Fatty Liver Disease N/A
Completed NCT01992809 - Omega 3 Supplementation in Fatty Liver Phase 3
Completed NCT00063635 - Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) Phase 3
Completed NCT00244569 - Development of a Breath Test for Monitoring Patients With Liver Disease Phase 3
Recruiting NCT03972319 - Omega-3 Supplementation for LIver VolumE Reduction Study (OLIVER) Study Early Phase 1
Completed NCT03141008 - Evaluation of Liver and Cardiometabolic Health Benefits on Low Carbohydrate Ketogenic Diet
Completed NCT03614039 - Effect of Probiotic and Smectite Gel on NAFLD N/A
Recruiting NCT05125757 - Lifestyle Modification in Psoriatic Patients With Fatty Liver N/A
Recruiting NCT05370053 - The Availability of the Enhanced Liver Fibrosis (ELF) Test Affects the Rate of Diagnosis of Nonalcoholic Steatohepatitis (NASH) With Fibrosis in Patients Referred to Hepatology N/A
Recruiting NCT04371042 - PROtocol of Metabolic and Cryptogenic livEr Disease regisTry for intEgration of Omic Studies
Completed NCT04004273 - Diabetes, Exercise and Liver Fat (DELIVER) N/A
Completed NCT02520609 - Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
Recruiting NCT02265276 - A Prospective, Randomized Trial to Compare saroGLitazar With pioglitAZone in Nonalcoholic Fatty livEr Disease Phase 3
Completed NCT02347007 - Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults N/A
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3